Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Seidman AD, Brufsky A, Ansari RH, Hart LL, Stein RS, Schwartzberg LS, Stewart JF, Russell CA, Chen SC, Fein LE, De La Cruz Vargas JA, Kim SB, Cavalheiro J, Zhao L, Gill JF, Obasaju CK, Orlando M, Tai DF.
Seidman AD, et al. Among authors: ansari rh.
Ann Oncol. 2011 May;22(5):1094-1101. doi: 10.1093/annonc/mdq578. Epub 2010 Nov 17.
Ann Oncol. 2011.
PMID: 21084429
Free article.
Clinical Trial.